Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex. Its earlier-stage clinical pipeline also includes INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug for rare pulmonary disorders. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INSM
Previous Symbol
CUSIPN/A
Phone908-977-9900
Debt
Debt-to-Equity Ratio1.07
Current Ratio10.06
Quick Ratio10.06
Price-To-Earnings
Trailing P/E Ratio-5.70
Forward P/E Ratio-4.01
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.78 per share
Price / Book4.36
Profitability
EPS (Most Recent Fiscal Year)($2.89)
Net Income$-192,640,000.00
Net MarginsN/A
Return on Equity-81.18%
Return on Assets-45.16%
Miscellaneous
Employees214
Outstanding Shares77,090,000
Market Cap$1.24 billion
OptionableOptionable
Insmed (NASDAQ:INSM) Frequently Asked Questions
What is Insmed's stock symbol?
Insmed trades on the NASDAQ under the ticker symbol "INSM."
How were Insmed's earnings last quarter?
Insmed Incorporated (NASDAQ:INSM) announced its quarterly earnings results on Tuesday, October, 30th. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.06) by $0.08. View Insmed's Earnings History.
When is Insmed's next earnings date?
What price target have analysts set for INSM?
6 brokerages have issued twelve-month target prices for Insmed's shares. Their forecasts range from $25.00 to $43.00. On average, they anticipate Insmed's stock price to reach $37.00 in the next year. This suggests a possible upside of 135.1% from the stock's current price. View Analyst Price Targets for Insmed.
What is the consensus analysts' recommendation for Insmed?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insmed.
Has Insmed been receiving favorable news coverage?
Headlines about INSM stock have been trending somewhat positive on Wednesday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Insmed earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Are investors shorting Insmed?
Insmed saw a increase in short interest in October. As of October 15th, there was short interest totalling 12,523,101 shares, an increase of 18.3% from the September 28th total of 10,582,492 shares. Based on an average daily volume of 2,037,905 shares, the days-to-cover ratio is currently 6.1 days. Currently, 17.1% of the shares of the stock are sold short. View Insmed's Current Options Chain.
Who are some of Insmed's key competitors?
Some companies that are related to Insmed include Loxo Oncology (LOXO), United Therapeutics (UTHR), HUTCHISON CHINA/S (HCM), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO), Agios Pharmaceuticals (AGIO), Horizon Pharma (HZNP), FibroGen (FGEN), Emergent Biosolutions (EBS), Ligand Pharmaceuticals (LGND), Array Biopharma (ARRY), Evotec (EVTCY), Intercept Pharmaceuticals (ICPT), Endo International (ENDP) and Madrigal Pharmaceuticals (MDGL).
Who are Insmed's key executives?
Insmed's management team includes the folowing people:
- Mr. William H. Lewis, Pres, CEO & Director (Age 49)
- Ms. Christine A. Pellizzari, Chief Legal Officer (Age 50)
- Mr. Roger Adsett, Chief Commercial Officer (Age 49)
- Dr. Paul Streck, Chief Medical Officer (Age 55)
- Mr. Paolo Tombesi, Chief Financial Officer (Age 54)
Who are Insmed's major shareholders?
Insmed's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (14.99%), Emerald Mutual Fund Advisers Trust (1.10%), Emerald Advisers Inc. PA (1.03%), Bellevue Group AG (0.73%), JPMorgan Chase & Co. (0.66%) and JPMorgan Chase & Co. (0.66%). Company insiders that own Insmed stock include Andrew T Drechsler, Christine A Pellizzari, Donald J Hayden Jr, Melvin Md Sharoky, Myrtle S Potter, Orlov S Nicole Schaeffer, Roger Adsett, Steinar J Engelsen and William Lewis. View Institutional Ownership Trends for Insmed.
Which major investors are selling Insmed stock?
INSM stock was sold by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, Chartwell Investment Partners LLC, Candriam Luxembourg S.C.A., Russell Investments Group Ltd., Los Angeles Capital Management & Equity Research Inc., Rice Hall James & Associates LLC and Rhumbline Advisers. Company insiders that have sold Insmed company stock in the last year include Donald J Hayden Jr and Orlov S Nicole Schaeffer. View Insider Buying and Selling for Insmed.
Which major investors are buying Insmed stock?
INSM stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., JPMorgan Chase & Co., Dimensional Fund Advisors LP, Emerald Mutual Fund Advisers Trust, Asymmetry Capital Management L.P., Bellevue Group AG, Emerald Advisers Inc. PA and FMR LLC. Company insiders that have bought Insmed stock in the last two years include Christine A Pellizzari, Melvin Md Sharoky, Roger Adsett, Steinar J Engelsen and William Lewis. View Insider Buying and Selling for Insmed.
How do I buy shares of Insmed?
Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Insmed's stock price today?
One share of INSM stock can currently be purchased for approximately $15.74.
How big of a company is Insmed?
Insmed has a market capitalization of $1.24 billion. The biopharmaceutical company earns $-192,640,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis. Insmed employs 214 workers across the globe.
What is Insmed's official website?
How can I contact Insmed?
Insmed's mailing address is 10 Finderne Avenue Building 10, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]
MarketBeat Community Rating for Insmed (NASDAQ INSM)
MarketBeat's community ratings are surveys of what our community members think about Insmed and other stocks. Vote "Outperform" if you believe INSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INSM will underperform the S&P 500 over the long term. You may vote once every thirty days.
